Clinical Trial Update: Safety, Tolerability and Efficacy of Weekly TV-1106 in Adults With Growth Hormone Deficiency [Phase 2]

View source ↗

Summary

Phase 2 trial assessing safety, tolerability, and efficacy of weekly TV-1106 in adults with growth hormone deficiency has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Growth Hormone Deficiency

Drugs mentioned

• TV-1106 (TV-1106)

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: Growth Hormone Deficiency | Phase 2 | Status: COMPLETED